Table 4 The changes of accompanying symptoms in migraine attacks with galcanezumab treatment
From: Real-life experiences with galcanezumab and predictors for treatment response in Turkey
Symptom in migraine attack | No previous complaint n (%) | No improvement n (%) | ≤%50 improvement n (%) | >% 50–99 improvement n (%) | 100% improvement n (%) |
|---|---|---|---|---|---|
Nausea | 86 (18.1) | 56 (11.8) | 37 (7.8) | 155 (32.6) | 142 (29.8) |
Vomiting | 280 (58.8) | 22 (4.6) | 14 (29.0) | 46 (9.7) | 114 (23.9) |
Photophobia | 51 (10.7) | 84 (17.6) | 69 (14.5) | 166 (34.9) | 106 (22.3) |
Phonophobia | 61 (12.8) | 72 (15.1) | 78 (16.4) | 166 (34.9) | 99 (20.8) |
Osmophobia | 177 (37.2) | 65 (13.7) | 43 (9.0) | 112 (23.5) | 79 (16.6) |
Aggravation* | 130 (27.3) | 70 (14.7) | 64 (13.4) | 137 (28.8) | 75 (15.8) |